Middle East and Africa Hemoglobinopathies Market Report and Forecast 2024-2032

The global hemoglobinopathies market was valued at USD 6.9 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising prevalence of genetic disorders. It is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032, with the values likely to attain USD 15.9 billion by 2032.

Middle East and Africa Hemoglobinopathies Market Outlook

• Recent data reveals that thalassemia and sickle cell anemia cause a substantial impact on morbidity and mortality. The high prevalence of hemoglobinopathies which can be attributed to the genetic predisposition and high rates of consanguineous marriages in the region is expected to fuel market demand.
• One of the major Middle East and Africa hemoglobinopathies market trends is the surge in regulatory approvals of advanced therapies by health authorities. In January 202 4, the Saudi Food and Drug Authority (SFDA) approved Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, a one-time gene-editing therapy leveraging a gene-editing tool called CRISPR/Cas9 to treat sickle cell disease (SCD) in adults and adolescents aged 12 and above.
• The market share is influenced by the increasing awareness campaigns coupled with the rising healthcare expenditures, leading to early diagnosis and better management of these inherited disorders.

Middle East and Africa Hemoglobinopathies Market Analysis

Hemoglobinopathies comprise a group of genetic disorders affecting the structure, function, or production of hemoglobin. The advancements in the global hemoglobinopathies market are increasingly being introduced into the Middle East and African countries. The penetration of such new and innovative treatments in the regional market are positively impacting the standard of care and clinical outcomes for patients with conditions like sickle cell disease and thalassemia. Moreover, the increasing awareness campaigns and advocacy efforts coupled with the rising healthcare expenditure are leading to early diagnosis and better management of these inherited disorders which are poised to significantly contribute to the Middle East and Africa hemoglobinopathies market growth.

The high prevalence of hemoglobinopathies in the region which can be attributed to the genetic predisposition and high rates of consanguineous marriages directly affects the market dynamics. Recent data reveals that thalassemia and sickle cell anemia cause a substantial impact on morbidity and mortality among the affected individuals. Alpha-thalassemia is reported to be prevalent in the Middle Eastern countries. In Saudi Arabia, beta-thalassemia and sickle cell anemia are estimated to be 13.6 and 49.6 per 1000 population, respectively . The growing burden of these hemoglobin disorders is projected to fuel the need for effective diagnostics and treatment solutions to manage such conditions, thereby boosting the Middle East and Africa hemoglobinopathies market demand.

One of the major market trends is the surge in regulatory approvals of novel treatments by the health agencies in the region. In January 202 4, the Saudi Food and Drug Authority (SFDA) approved Casgevy (exagamglogene autotemcel) which is a one-time gene-editing therapy leveraging a gene-editing tool called CRISPR/Cas9 to treat sickle cell disease (SCD) in adults and adolescents aged 12 and above who experience recurrent vaso-occlusive crises. Developed jointly by biotechnology companies Vertex Pharmaceuticals and CRISPR Therapeutics, this gene editing therapy represents the first medicine to receive and be approved via the SFDA Breakthrough Designation pathway. The presence of such regulatory reforms that accelerate the review of therapies that address unmet medical needs is likely to elevate the market value.

Middle East and Africa Hemoglobinopathies Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Thalassemia
• Sickle Cell Disease
• Other Hb Variants Diseases

Market Breakup by Treatment

• Stem-Cell Transplantation
• Blood Transfusions
• Analgesics
• Antibiotics
• Ace Inhibitors
• Hydroxyurea
• Monoclonal Antibody Medication
• Others

Market Breakup by Test Type

• Routine Red Blood Cell (RBC) Count
• Genetic Testing
• Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
• Hemoglobin Isoelectric Focusing (Hb IEF)
• Hemoglobin electrophoresis (Hb ELP)
• Hemoglobin Solubility Test

Market Breakup by End User

• Hospitals and Clinics
• Diagnostics Laboratories
• Others

Market Breakup by Country

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Leading Players in the Middle East and Africa Hemoglobinopathies Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Pfizer Limited
• Merck KGaA
• Alnylam Pharmaceuticals, Inc.
• Sanofi
• Neusoft Corporation
• Emmaus
• Biogen

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Middle East and Africa hemoglobinopathies market forecast outlook for 2024-2032?
The Middle East and Africa hemoglobinopathies market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.

What are the major factors aiding the Middle East and Africa hemoglobinopathies market demand?
The rising prevalence of thalassemia and sickle cell anemia is fuelling the demand for the market.

What are the major Middle East and Africa hemoglobinopathies market trends?
One of the significant trends in the market is the surge in regulatory approvals of advanced therapies by health authorities. In January 2024, the Saudi Food and Drug Authority (SFDA) approved Casgevy, a one-time gene-editing therapy to treat sickle cell disease (SCD) in adults and adolescents aged 12 and above.

What is the market segmentation based on the type?
Based on the type, the market is segmented into thalassemia, sickle cell disease, and other Hb variant diseases.

What are the various treatments available in the market?
Treatments available in the market include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, and monoclonal antibody medication, among others.

What is the market breakup by test type?
By test type, the market is divided into routine red blood cell (RBC) count, genetic testing, hemoglobin by high performance liquid chromatograph (Hb HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.

What are the major end users of the market?
End users of the market are hospitals, clinics, and diagnostics laboratories, among others.

What is the market segmentation by countries?
The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.

Who are the key players involved in the Middle East and Africa hemoglobinopathies market?
The key players in the market are Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Limited, Merck KGaA, Alnylam Pharmaceuticals, Inc., Sanofi, Neusoft Corporation, Emmaus, and Biogen.


This product will be delivered within 5-7 business days.